Crinecerfont
Capsule · trading as Crenessity
To Be Discontinued
FDA shortage record
- Substance
- Crinecerfont
- Brand name
- Crenessity
- Manufacturer
- Neurocrine Biosciences, Inc.
- Dosage form
- Capsule
- Presentation
- Crenessity, Capsule, 25 mg (NDC 70370-5025-1)
- Route(s)
- ORAL
- Therapeutic category
- Endocrinology/Metabolism
- Package NDC
70370-5025-1- Initially posted
- 04/28/2026
- Discontinued
- 04/28/2026
- Current FDA status
- To Be Discontinued
Reason and context
Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 858-617-7600.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
fd3a6fbd-9137-428a-ba46-df6606f07d28). - FDA UNII identifier:
MFT24BX55I. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.